Stockscreener 앱 받기
37.87
0.16%
-0.06
시간 외 거래:
37.99
0.12
+0.32%
Cogent Biosciences Inc 주식(COGT)의 최신 뉴스
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences set to report earnings ahead of FDA decisions By Investing.com - Investing.com Canada
Cogent Biosciences set to report earnings ahead of FDA decisions - Investing.com
Is Cogent Biosciences Inc (COGT) Worth the Risk After Q2 Earnings Miss? GF Score: 25/100 - GuruFocus
Form 8K Cogent Biosciences Inc For: 10 August By Investing.com - Investing.com Australia
Cogent Biosciences Q2 EPS of $(0.52) beats estimates by 8.77% - scanx.trade
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results - MarketBeat
Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, Vs. FactSet Est of $98M Loss - moomoo.com
Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach - Quiver Quantitative
Cogent Biosciences Q2 net loss widens on higher expenses - TradingView
Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib - Stock Titan
Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec. - Stock Titan
Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Cogent Biosciences (COGT) Earnings Date and Reports 2026 - MarketBeat
Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Loss-Making Cogent Biosciences, Inc. (NASDAQ:COGT) Expected To Breakeven In The Medium-Term - Moomoo
Cogent Biosciences (COGT) Stock Analysis: High Potential with 29.78% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts - Quiver Quantitative
Defilade Capital Management L.P. Sells 216,029 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Seven Fleet Capital Management LP Sells 64,700 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis: A Biotech with Promising Upside and Analyst Confidence - DirectorsTalk Interviews
Principal Financial Group Inc. Trims Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Redmile Group LLC Decreases Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Projected to Release Earnings on Tuesday - MarketBeat
BlackRock (COGT holder) discloses 8.0% ownership in Cogent Biosciences common stock - Stock Titan
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cogent Biosciences Inc (COGT) Cash Flow - TradingKey
COGT|Cogent Biosciences Inc|Price:40.450|Chg%:+0.690 - TradingKey
Sona Asset Management US LLC Decreases Position in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT|Cogent Biosciences Inc|Price:38.705|Chg%:+0.005 - TradingKey
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
COGT|Cogent Biosciences Inc|Price:42.910|Chg%:+4.050 - TradingKey
346,104 Shares in Cogent Biosciences, Inc. $COGT Acquired by Weiss Asset Management LP - MarketBeat
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
COGT|Cogent Biosciences Inc|Price:39.760|Chg%:-0.480 - TradingKey
Atika Capital Management LLC Sells 212,800 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
SEB Asset Management AB Acquires New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT6232219 Bond Risk Profile - TradingView
COGT6232219 Bond Coupon Profile — Rate & Payments - TradingView
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
COGT6232219 Bond Profile — Key Metrics - TradingView
Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib - Yahoo Finance
Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Enterprise value to EBITDA forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation - Sahm
Price to book forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
1.80%
1.77%
자본화:
|
볼륨(24시간):